Investor Relations

English Français

Latest News

Apr 17, 2025

Medexus Successfully Completes Agreement for Public Reimbursement of Trecondyv (treosulfan for injection) in Quebec, Canada

View Press Release

Apr 7, 2025

Medexus Provides Update on Progress of Commercialization of GRAFAPEX (treosulfan) for Injection

Mar 14, 2025

Medexus Completes Agreement to Return US Commercialization Rights for Gleolan to NX Development Corp.

View All News

2025 Bloom Burton & Co. Health Care Investor Conference

View Event View All

Treosulfan Pivotal Study Results with Dr. Filippo Milano, MD

Q3 2025

Quarter Ended Dec 31, 2024

Earnings Release

PDF HTML

Audio

Earnings Webcast

Management Discussion & Analysis

PDF

Financial Statements

PDF

Company Overview

Medexus Pharmaceuticals, Inc. is a leading innovative specialty pharmaceutical company with a strong North American commercial platform. Our product portfolio features leading products that address a variety of diseases, including allergy, dermatology, hematology, oncology and rheumatology.

The leading prescription products are Rasuvo and Metoject, unique formulations of methotrexate (auto-injector and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, an innovative allergy medication with a unique mode of action; IXINITY, for control & prevention of bleeding episodes & for perioperative management of patients with Hemophilia B; Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery; and Trecondyv, indicated in combination with fludarabine as part of conditioning treatment prior to allogeneic hematopoietic stem cell transplantation (alloHSCT).

Investor Contact Information

Company

Medexus Pharmaceuticals, Inc.
10 King Street East, Suite 600
Toronto, ON M5C 1C3
Canada
T: 877-422-5242